Analytical Determination of Proanthocyanidin Content and its Association with Label-Declared Proanthocyanidin Amounts...

Proanthocyanidins (PACs) represent the primary bioactive compounds in cranberries recognized for reducing urinary tract infection (UTI) recurrence. Accurate PAC measurement is essential for reliable labeling, evaluating therapeutic efficacy, and guiding consumer decisions. The 4-dimethylamino cinnamaldehyde (DMAC) assay remains the predominant method for quantifying PACs in cranberry dietary supplements (DSs). However, the influence of methodological variability in commercial laboratories remains unclear.

To quantify PAC content and evaluate label accuracy in commonly consumed United States cranberry DS, and to assess interlaboratory variability using commercially implemented DMAC protocols.

Fifty-three cranberry DS products (extracts, concentrates, or whole fruit powders) were analyzed for PACs by 4 independent commercial laboratories using harmonized extraction solvents and 2 standards (procyanidin A2 and cranberry PAC), while allowing laboratory-specific DMAC workflows for soluble PAC quantification. Insoluble PACs were quantified by butanol-hydrochloric acid assay in 1 laboratory. Statistical analyses included pairwise comparisons, meta-analysis, and heterogeneity testing.

Overall, 3 of 53 products contained soluble PAC levels at or above 36 mg/d, the level associated with UTI risk reduction. Notably, 13 of 16 (81.3%) extract-based products provided PAC concentrations well below this level despite having higher average soluble PAC content than concentrate-based DS, and higher, although not statistically significantly, than whole fruit powder-based products. Products declaring PAC content contained significantly less than stated. Interlaboratory variability (%relative standard deviation) for in-house controls and products with >3.3 mg/d PAC ranged from 22.1% to 31.6%. Concentrate and fruit powder-based products contained more insoluble PAC than the extract-based products.

Soluble PAC amounts in most commercial cranberry DS differ substantially from label claims. Although interlaboratory variability was high for low PAC products, variability was acceptable for products containing ≥3.3 mg/d soluble PAC. Current industry DMAC practices can distinguish clinically relevant PAC potencies. Findings highlight the need for more stable formulations and greater transparency in PAC labeling.